EQT Nears €9.6 Billion Deal for Molecular Testing Firm Qiagen

EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.